AHA 2023 | Use of Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

Subclinical atrial fibrillation (AF), generally asymptomatic and of short duration, often requires continuous long-term monitoring using pacemakers or defibrillators for its detection. While subclinical AF is linked to an increased risk of stroke, the usefulness of oral anticoagulation as a treatment remains uncertain.

AHA 2023 | ORBITA-2: Angioplastia coronaria vs placebo en angina estable para la reducción de síntomas

In a double-blind randomized trial, one group received apixaban and the other received aspirin. The primary efficacy endpoint was the rate of systemic embolism or stroke (SE), while the primary safety endpoint focused on the rate of major bleeding.

The sample included 4012 patients with an average age of 76 years and an average CHA2DS2-VASc score of 3.9. Of them, 36% were women. In terms of the primary efficacy endpoint, the incidence in the apixaban group was 0.78%, compared with 1.24% in the aspirin group (hazard ratio [HR]: 0.63; 95% confidence interval [CI]: 0.45-0.88; P=0.007). The rate of major bleeding was 1.71% in the apixaban group and 0.94% in the aspirin group (HR: 1.8; 95% CI: 1.26-2.57; P=0.001).

Conclusion

Among patients with subclinical AF, the use of apixaban led to a lower risk of systemic embolism or stroke compared with aspirin, although it was also associated with an increased risk of major bleeding.

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation.

Reference: Jeff S. Healey, M.D et al. 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Direct Oral Anticoagulants for Ventricular Thrombus After STEMI

While the incidence of intracavitary thrombi after acute myocardial infarction (AMI) has decreased thanks to optimized primary angioplasty times, some studies report rates of...

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Acute Coronary Syndrome with Multivessel Disease: Best Revascularization Strategy

The gold standard treatment for acute coronary syndrome (ACS), especially acute myocardial infarction (AMI) is primary angioplasty (PCI). However, 40 to 70% of ACS...

Improved Ejection Fraction in Chronic Total Occlusion?

Chronic total occlusions (CTO) represent a significant challenge in the current clinical practice, seeing as CTO percutaneous coronary intervention (PCI) is complex and involves...

TAVR and Surgical Bailout: Temporal Trends and Clinical Implications

The evolution of transcatheter aortic valve replacement (TAVR), both regarding its planning and execution, has resulted in minimally invasive interventions with high safety levels....